Impact of the serogroup a meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity

Clinical Infectious Diseases

Volumn 56, Issue 3, 2013, Pages 354-363

  Kristiansen, Paul A ^a   Diomandé, Fabien ^c,f   Ba, Absatou Ky ^c   Sanou, Idrissa ^d,e   Ouédraogo, Abdoul Salam ^e   Ouédraogo, Rasmata ^c   Sangaré, Lassana ^d   Kandolo, Denis ^c   Aké, Flavien ^c   Saga, Inger Marie ^a   Clark, Thomas A ^f   Misegades, Lara ^f   Martin, Stacey W ^f   Thomas, Jennifer Dolan ^f   Tiendrebeogo, Sylvestre R ^c   Hassan King, Musa ^g   Djingarey, Mamoudou H ^c   Messonnier, Nancy E ^f   Préziosi, Marie Pierre ^g,h   Laforce, F Marc ^g   Caugant, Dominique A ^a,b   more..

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^d CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^e Centre Hospitalier Universitaire Souro Sanou   (Burkina Faso)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g Meningitis Vaccine Project   (France)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

carriage; conjugate vaccine; herd immunity; meningitis belt; Neisseria meningitidis

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; CHILD; FALSE NEGATIVE RESULT; FEMALE; HUMAN; IMMUNITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; NONHUMAN; OROPHARYNX; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; SCHOOL CHILD; SEASON; SENSITIVITY AND SPECIFICITY; THROAT CULTURE; VACCINATION;

ADOLESCENT; ADULT; BURKINA FASO; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNITY, HERD; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PREVALENCE; VACCINATION; YOUNG ADULT;

EID: 84872282456     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis892     Document Type: Article

References (31)

1. Lapeyssonnie L. La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ 1963; 28(Suppl):3-114.
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:B51-63.
3. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31:3-14.
4. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:9-32.
5. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63.
6. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005; 43:5129-35.
7. Koumare B, Ouedraogo-Traore R, Sanou I, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007; 25:A37-41.
8. World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. Communicable Disease Surveillance and Response Publications, Geneva, Switzerland. 1998. Available at: http://www.who.int/csr/ resources/publications/meningitis/WHO-EMC-BAC-98-3-EN/en/. Accessed 15 August 2012.
9. Wuorimaa T, Kayhty H, Eskola J, Bloigu A, Leroy O, Surcel HM. Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol 2001; 53:422-8.
10. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-30.
11. Forleo-Neto E, De Oliveira CF, Maluf EMCP, et al. Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharidetetanus toxoid conjugate vaccine in combination with diphtheriatetanus toxoids- pertussis vaccine. J Infect Dis 1999; 180:1153-8.
12. Maiden MCJ, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43.
13. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J 2003; 326:365-6.
14. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010; 17:325-34.
15. LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25:A97-100.
16. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal a conjugate vaccine in Africans. N Engl J Med 2011; 364:2293-304.
17. Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012; 30(Suppl 2):B40-5.
18. LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011; 30:1049-57.
19. Kristiansen PA, Diomande F, Wei SC, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011; 18:435-43.
20. Taha M-K. Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 2000; 38:855-7.
21. Kristiansen PA, Ouedraogo AS, Sanou I, et al. Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso. Trans R Soc Trop Med Hyg 2012; 106:289-97. 22. World Health Organization. Inter-country Support Team - West Africa. Meningitis Weekly Bulletin. Available at: http://www.who.int/csr/disease/meningococcal/epidemiological/en. Accessed 15 August 2012.
22. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501-8.
23. Scott JR, Millar EV, Lipsitch M, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities. J Infect Dis 2012; 205: 280-8.
24. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012; 34:385-99.
25. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non- pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54.
26. Delrieu I, Yaro S, Tamekloe TAS, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011; 6:e19513.
27. Leimkugel J, Hodgson A, Forgor AA, et al. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007; 4:e101.
28. Farrington CP. On vaccine efficacy and reproduction numbers. Math Biosci 2003; 185:89-109.
29. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005; 162:89-100.
30. Stephens DS. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering ransmission dynamics. Trans Am Clin Climatol Assoc 2011; 122:115-22.
31. Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007; 12:1409-21.0